Literature DB >> 22672476

Mucopolysaccharidosis type I (Hurler syndrome) and anesthesia: the impact of bone marrow transplantation, enzyme replacement therapy, and fiberoptic intubation on airway management.

Katherine Kirkpatrick1, James Ellwood, Robert W M Walker.   

Abstract

AIM: To assess the effect of bone marrow transplantation (BMT), enzyme replacement therapy (ERT), and a fiberoptic endotracheal intubation technique in patients with mucopolysaccharidosis type I (MPS I, Hurler syndrome).
BACKGROUND: The mucopolysaccharidoses are inherited metabolic conditions with a well-documented association with difficult airway management. We present the largest series to date of patients with Hurler syndrome (MPS I) and look at the impact of new treatments, such as BMT and ERT, on anesthesia and airway management. METHODS/MATERIALS: We carried out a retrospective chart review of patients with MPSI undergoing anesthesia over 9 years at the Royal Manchester Children's Hospital. Data were collected on incidence of difficult and failed intubation and airway difficulties under anesthesia.
RESULTS: There were 39 patients identified, of which 20 had the attenuated form of MPS I and received ERT, 18 were treated by BMT and one patient received neither treatment. These patients had a total of 114 general anesthetics for 141 procedures. The incidence of airway complications overall is lower than previously reported at 31%. Patients with the attenuated form of the disease on ERT still have a high incidence of airway problems at 57% and a failed intubation rate of 3%. BMT patients on the other hand have a much lower incidence of airway complications at 14%, and there were no failed intubations in this group.
CONCLUSIONS: Managing the MPS1 patient continues to be a challenge but with treatment and newer forms of airway management it is improving.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22672476     DOI: 10.1111/j.1460-9592.2012.03897.x

Source DB:  PubMed          Journal:  Paediatr Anaesth        ISSN: 1155-5645            Impact factor:   2.556


  12 in total

Review 1.  Clinical neurogenetics: neuropathic lysosomal storage disorders.

Authors:  Gregory M Pastores; Gustavo H B Maegawa
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

Review 2.  Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future.

Authors:  Madeleine Taylor; Shaukat Khan; Molly Stapleton; Jianmin Wang; Jing Chen; Robert Wynn; Hiromasa Yabe; Yasutsugu Chinen; Jaap Jan Boelens; Robert W Mason; Francyne Kubaski; Dafne D G Horovitz; Anneliese L Barth; Marta Serafini; Maria Ester Bernardo; Hironori Kobayashi; Kenji E Orii; Yasuyuki Suzuki; Tadao Orii; Shunji Tomatsu
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-14       Impact factor: 5.742

3.  Spinal cord issues in adult patients with MPS: transition of care survey.

Authors:  Kemel A Ghotme; Fernando Alvarado-Gomez; Christina Lampe; Klane K White; Martha Solano-Villareal; Roberto Giugliani; Paul R Harmatz
Journal:  Childs Nerv Syst       Date:  2018-05-27       Impact factor: 1.475

4.  Hurler syndrome (Mucopolysaccharidosis type I).

Authors:  Reuben Grech; Leo Galvin; Alan O'Hare; Seamus Looby
Journal:  BMJ Case Rep       Date:  2013-03-25

5.  Emergency bronchoscopy for foreign-body aspiration in a child with type I mucopolysaccharidosis: a challenging airway management experience.

Authors:  Pinar Kendigelen; Yusuf Tunali; Ayse Tutuncu; Gulruh Ashyralyyeva; Senol Emre; Guner Kaya
Journal:  J Anesth       Date:  2016-05-04       Impact factor: 2.078

6.  Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome.

Authors:  Abhijit Ricky Pal; Eveline J Langereis; Muhammad A Saif; Jean Mercer; Heather J Church; Karen L Tylee; Robert F Wynn; Frits A Wijburg; Simon A Jones; Iain A Bruce; Brian W Bigger
Journal:  Orphanet J Rare Dis       Date:  2015-04-10       Impact factor: 4.123

Review 7.  Anesthesiological risks in mucopolysaccharidoses.

Authors:  Alessandra Moretto; Maria Grazia Bosatra; Laura Marchesini; Simonetta Tesoro
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

Review 8.  Anaesthesia and airway management in mucopolysaccharidosis.

Authors:  Robert Walker; Kumar G Belani; Elizabeth A Braunlin; Iain A Bruce; Henrik Hack; Paul R Harmatz; Simon Jones; Richard Rowe; Guirish A Solanki; Barbara Valdemarsson
Journal:  J Inherit Metab Dis       Date:  2012-11-30       Impact factor: 4.982

Review 9.  Mucopolysaccharidosis Type I: A Review of the Natural History and Molecular Pathology.

Authors:  Christiane S Hampe; Julie B Eisengart; Troy C Lund; Paul J Orchard; Monika Swietlicka; Jacob Wesley; R Scott McIvor
Journal:  Cells       Date:  2020-08-05       Impact factor: 6.600

10.  Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy.

Authors:  Abhijit Ricky Pal; Jean Mercer; Simon A Jones; Iain A Bruce; Brian W Bigger
Journal:  PLoS One       Date:  2018-09-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.